2018 Symposium on Tumor MicroEnvironment and Cancer Immunotherapy
With the approval of many PD-1 checkpoint inhibitors and the success of lots of clinical trials on cancer immunotherapy, people become more confident with overwhelming the incurable disease. However, there still remain unsolved problems in tumor microEnvironment & tumor immunity.
会议主页